Disc Medicine Inc KOL Investor Event Transcript
Good afternoon, and thank you for joining us today. My name is John Quisel, and I'm the CEO here at Disc medicine.
Today, we're going to discuss a disorder called Erythropoietic protoporphyria, also referred to as EPP. This is a rare and severe genetic disorder. And our drug development program for the molecule called Bitopertin is now in multiple Phase 2 trials to treat this disorder.
Before I begin, I should note that we may be making forward-looking statements today. Each should be take about context with the language on the slide, as well as in our 10-K and other security filings. We've got an exciting program today. We're delighted to be joined by Professor Bruce Wang from University of California, San Francisco, and also Professor Jean-Charles Deybach, who joins us from Paris University and was the former head of the French Porphyria Centre. And then lastly, we'll have a presentation from Will Savage, the Chief Medical Officer here at Disc Medicine.
First, I'll provide a background about Disc Medicine. We are building what we hope to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |